Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Non Operating Income (2016 - 2025)

Cytosorbents' Non Operating Income history spans 15 years, with the latest figure at -$1.1 million for Q4 2025.

  • Quarterly results put Non Operating Income at -$1.1 million for Q4 2025, up 81.03% from a year ago — trailing twelve months through Dec 2025 was $6.1 million (up 203.23% YoY), and the annual figure for FY2025 was $6.1 million, up 203.22%.
  • Non Operating Income for Q4 2025 was -$1.1 million at Cytosorbents, down from -$709000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $5.6 million in Q2 2025 to a low of -$5.9 million in Q4 2024.
  • The 5-year median for Non Operating Income is -$716500.0 (2024), against an average of -$145968.2.
  • Peak annual rise in Non Operating Income hit 1034.68% in 2022, while the deepest fall reached 1120.28% in 2022.
  • Year by year, Non Operating Income stood at -$481194.0 in 2021, then surged by 1034.68% to $4.5 million in 2022, then tumbled by 40.13% to $2.7 million in 2023, then plummeted by 317.73% to -$5.9 million in 2024, then soared by 81.03% to -$1.1 million in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$1.1 million, -$709000.0, and $5.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.